The raised revenue guidance is a clear positive, but the volixibat delay and GAAP EPS miss temper the outlook. Traders should watch for upcoming brelovitug Phase 3 data (Q3/Q4 2026) and the zilurgisertib PDUFA date (Sept 26, 2026) as key catalysts. The convertible note issuance strengthens the balance sheet but adds dilution risk.
Drugs in focus
MIRM drug pipeline →brelovitug
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3 (completed)
- Time to market
- Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
- Next catalyst
- BLA filing · H1 2027
What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $94.12entry
- T+1 · 3mo ago +6.94%α +6.33% · $100.65
- T+5 · 3mo ago +4.95%α +3.73% · $98.77
- T+20 · 3mo ago +6.92%α +6.32% · $100.63
- T+60 · 18d ago −9.69%α −8.01% · $85.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2M, a 38% YoY increase, and raised full-year guidance to $680M-$700M. However, GAAP EPS was -$1.06, a significant miss vs the -$0.75 consensus, driven by heavy R&D and SG&A spending. The volixibat NDA submission was delayed to H1 2027 after the FDA recommended a Phase 3 study, a key pipeline setback. The strong commercial performance and raised guidance are offset by the earnings miss and the volixibat delay, resulting in a mixed outlook.
Key Financial Metrics
Key Facts
- Q2 2026 net product sales of $176.2M, up 38% YoY from $127.8M.
- Full-year 2026 net product sales guidance raised to $680M-$700M from $660M-$680M.
- GAAP net loss per share of -$1.06 vs consensus of -$0.75 (a miss).
- Volixibat NDA submission for PSC delayed to H1 2027 after FDA recommended a Phase 3 study.
- Issued $690M of 0.00% convertible senior notes due 2032 and settled $237.2M of 4.00% notes.
- Cash and investments of $561.3M as of June 30, 2026.
Financial Impact
Revenue beat by $9.8M (+5.9%) vs $166.4M consensus; EPS missed by -$0.31 (-41.3%) vs -$0.75 consensus.
Risk Factors
- Volixibat NDA submission delay to H1 2027 after FDA requested a Phase 3 study.
- GAAP EPS miss of -$1.06 vs consensus -$0.75, driven by high operating expenses.
- Potential dilution from the $690M convertible note issuance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759425-26-000044 |
| Document: mirm-20260805.htm | 0001759425-26-000044 |
| Document: 0001759425-26-000044-index-headers.html | 0001759425-26-000044 |
| Document: 0001759425-26-000044-index.html | 0001759425-26-000044 |
| Document: 0001759425-26-000044.txt | 0001759425-26-000044 |
| 8-K Data (Synthetic) | 0001759425-26-000044 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers